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A B S T R A C T
Recent studies have questioned the effect of maternal derived antibodies (MDAs) to protect piglets against infection
with influenza A virus (IAV). The lack of protection against IAV infections provided by MDAs has encouraged alter-
native vaccination strategies targeting young piglets in an attempt to stimulate an early antibody response. There is a
lack of studies documenting the efficacy of piglet vaccination. In the present study, we monitored a group of vaccinated
and non-vaccinated piglets in a Danish sow herd that initiated piglet vaccination with ¼ dose of an inactivated swine
influenza vaccine at the time of castration (day 3–4). A total of 160 piglets from 11 sows were included and either
vaccinated with 0.5mL inactivated swine influenza vaccine or sham-vaccinated. Fromweek 0 until week 6, all included
piglets were clinically examined and nasal swapped once per week and weighed at weeks 0, 3 and 6. Blood samples
were collected from sows at week 0 and from piglets at week 3. Vaccination of piglets had limited effect on clinical
signs, body weight, antibody development and viral shedding, within the first 6weeks of life. At least 50% of all pigs of
each treatment group tested positive for IAV at week 2, and very early onset of IAV shedding was observed. In total, 18
pigs were IAV positive in nasal swabs for more than one consecutive sampling time indicating prolonged shedding and
14 pigs were IAV positive with negative samplings in between indicating re-infection with the same IAV strain.
1. Introduction
Influenza A virus (IAV) infection in pigs can lead to clinical signs of
respiratory disease and compromised animal welfare, increased use of
antibiotics and negative impact on the productivity (Fablet et al., 2012;
Opriessnig et al., 2011; Vincent et al., 2014). Furthermore IAV is a zoo-
notic disease, which leaves swine herds as a reservoir for possible future
human IAV pandemics (Garten, 2009; Torremorell et al., 2012). These
factors emphasize the need for an optimal control strategy to minimize the
number of IAV positive pigs and herds. Recent studies documented
changes in the IAV dynamics, and it is now clear that epizootic infections,
in most cases, will establish enzootic status in affected herds (Cador et al.,
2017; Cappuccio et al., 2017; Diaz et al., 2017b; Ferreira et al., 2017a;
Loeffen et al., 2009; Pitzer et al., 2016; Rose et al., 2013; Simon-Grifé
et al., 2012). Several studies investigated the effects and benefits of ma-
ternally derived antibodies (MDAs) in protection against IAV infection in
the piglets, and these studies showed that MDAs do not provide full pro-
tection against IAV infection and clinical signs (Allerson et al., 2014; Cador
et al., 2016c, 2016b; Corzo et al., 2014; Diaz et al., 2017a; Markowska-
Daniel et al., 2011; Rose et al., 2013; Simon-Grifé et al., 2012). Moreover,
presence of MDAs at the time of primary infection may impair an active
humoral response making the piglet susceptible for a reinfection even with
the same strain (Cador et al., 2016a; Deblanc et al., 2018; Loeffen et al.,
2003). A previous study revealed that IAV infection can occur as early as
3 days of age despite the presence of MDA and IAV is highly prevalent in
both the farrowing unit and in nursery pigs early after weaning (Corzo
et al., 2014; Ferreira et al., 2017b; Rose et al., 2013; Ryt-Hansen et al.,
2019; Simon-Grifé et al., 2012). In Europe, there is no vaccine licensed for
use in pigs below 8weeks of age and sow vaccination strategies (mass sow
vaccination/pre-farrow) are widely applied for limiting the clinical impact
of IAV in piglets by ensuring uptake of MDAs in the piglets (Rajao et al.,
2014). However, the protection obtained through MDAs can, as mentioned
above, be sub-optimal and therefore different approaches to control IAV in
young piglets e.g. by vaccination are needed. The aim of the present field
study was therefore to monitor clinical signs, weight, antibody develop-
ment and viral shedding in piglets in a Danish herd that vaccinated piglets
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with a ¼ dose (0.5mL) of an inactivated swine influenza vaccine (Re-
spiporc FLU3, IDT Biologika) per piglet at the time of castration.
2. Materials and methods
2.1. The herd
This case took place in a Danish herd with 900 sows and 3500 pen
places for nursery pigs. The herd was according to the Danish Specific
Pathogen Free program (Svineproduktion, 2019) declared free from
Porcine Reproductive & Respiratory Syndrome Porcine virus (PRRSv).
No strict all in/all out strategy was performed in any of the units, and
stables were only cleaned and disinfected with hydrated lime between
the different batches of sows in the farrowing unit. No quarantine stable
was present for incoming gilts. In the farrowing unit, a high number of
nursing sows were used and the piglets were mingled more than once.
No vaccination against IAV had been used previously in the herd. All
piglets were vaccinated against Mycoplasma hyopneumoniae at day 4.
Recurrent problems with respiratory disease were seen and the herd
had previously tested positive for influenza A virus (subtype H1avN2).
2.2. Study design
A total of 160 piglets from 11 sows that farrowed on the same day
were selected for the study. To assure colostrum intake, no litter
equalization was allowed before castration at day 4, where all piglets
were ear tagged with consecutive numbers. All movements were re-
corded. Pigs with an odd ear tag number were injected intramuscularly
in the neck with 0.5 mL Respiporc FLU3 (VAC), corresponding to a
quarter of a dose and piglets with an even ear tag number were injected
with 0.5 mL of physiological saline, 9 mg/mL (control).
2.3. Data sampling
Clinical examination of all ear tagged pigs was performed weekly
and included registration of nasal discharge, conjunctivitis, lacrimation
and fecal soiling. In addition, the pigs were evaluated for body score
and “other diseases” including clinical signs of lameness, wounds, ec-
zema, umbilical hernia and CNS symptoms. Rectal temperature was
measured at the time of vaccination and one-day post vaccination on all
ear tagged pigs.
Weighing of all pigs was performed at weeks 0, 3 and 6 on a piglet
scale approved for pigs weighing between 200 g and 30 kg (Bjerringbro
Vægte Aps, Denmark).
Blood samples were drawn from vena cava cranialis of all ear tagged
pigs at week 3 and from vena jugularis of the sows at week 0. All blood
samples were collected in a vacutainer serum tube (Becton Dickinson,
Denmark). The blood samples were kept at 5 °C for a maximum of
2 days, until they were centrifuged at 3000 rpm for 10min and the
resulting serum was immediately analyzed.
Nasal swabs were collected from all piglets at the time of vaccina-
tion (week 0) and weekly thereafter until week 6. As not all the piglets
were weaned at the same age, sampling during week 4 was done either
in the farrowing unit (W4F) or in nursery unit (W4N). The swab, a small
rayon swab (Medical Wire, UK), was introduced in both nostrils where
it was turned 360 degrees. Afterwards, the swab was transferred into
the Sigma Virocult media (Medical Wire, UK), and kept at 2–8 °C for a
maximum of 2 days.
2.4. Laboratory analyses
2.4.1. Serology
The blood samples from sows and pigs were tested in a blocking
ELISA that detects antibodies targeting the NP gene, which is conserved
among the different Influenza A subtypes (IDEXX; Influenza A Ab Test;
IDEXX Laboratories, Inc.)
2.4.2. Pooling of samples and RNA extraction
The Sigma Virocult media (MWE, England) containing the swab was
vortexed and poured into a 1.5mL tube (Eppendorf), wherefrom 100 μL
were withdrawn for the pool. Five nasal swabs representing five pigs
were pooled in same tube. Vaccinated and control animals were pooled
in separate tubes. The pool was mixed and centrifuged and subse-
quently 200 μL was withdrawn and transferred to a tube containing
400 μL RLT-buffer (QIAGEN, Copenhagen, Denmark) containing 2-
Mercaptoethanol (Merck, Darmstadt, Germany). The RNA was ex-
tracted from the sample using the RNeasy mini kit (QIAGEN,) auto-
mated on the QIAcube (Qiagen, Hilden, Germany) using the large
sample protocol version 2.
2.4.3. Real time RT-PCRs
A previously published semi-quantitative real time RT-PCR assay
targeting the matrix gene of all IAVs (Nagy et al., 2010) was utilized to
determine if a pool was positive for influenza A virus. Briefly, the
OneStep RT-PCR kit (QIAGEN) was used with the published primers,
and all PCR reactions were run on the Rotor-Gene Q (QIAGEN) using
the following program: 50 °C, 30min; 95 °C, 15min; cycling 45×
(95 °C, 10 s, 60 °C 20 s, 64 °C 1 s, 68 °C 1 s, 72 °C 30 s). All PCR reactions
were run in duplicates, and the sample was only considered positive if
both duplicates gave a ct value. A pool was considered positive if it had
a Ct value<36. If a pool tested positive, the RNA was extracted from
the individual samples of the pool, using the same method as described
above. The RNA was then subjected to the same semi-quantitative real
time RT-PCR assay as described above to determine which of the in-
dividual pigs that was positive for IAV. All positive individual samples
with a Ct value< 31 were then tested in a multiplex real time RT-PCR
assay for the determination of the Influenza A subtype as previously
described (Ryt-Hansen et al., 2019).
2.4.4. Viral isolation and NGS
The nasal swab with the lowest Ct value, was selected for viral
isolation in MDCK cells. The MDCK cells were incubated at 37 °C in a
5% CO2 atmosphere in a viral growth media containing Minimum
Essential Medium Eagle (MEM) (Gibco, Carlsbad, CA, USA), 5% in-
activated fetal calf serum (FCS), Non-essential amino acids (NEAA),
2mM L-glutamine and Penicillin-streptomycin. The nasal swab was
subjected to sterile filtration using a 0.45 μM Millex-HP Millipore filter
(Merck, Germany), and 200 μL was then used for inoculation of cells
along with media containing MEM, NEAA, 2mM L-glutamine,
Penicillin-streptomycin and N-tosyl-L-phenylalanine chloromethyl ke-
tone (TPCK) treated Trypsin. After 24 h, the supernatant was harvested.
The RNA was extracted from the supernatant as described earlier, and
the RNA used as a template for a modified version of the one-tube PCR
protocol as previous described (Kai Lee, 2013). In short, the primers
MBTuni-12 and MBT-uni13 were used together with the SuperScript III
RT/Platinum Taq High Fidelity kit (Invitrogen, Denmark), and run on
the T3 thermocycler (Biometra, Denmark) with the following condi-
tions: 42 °C, 60min, 94 °C, 2min, 5× (94 °C, 30 s – 45 °C, 30 s - 68 °C,
180 s), 31× (94 °C, 30 s – 57 °C, 30 s – 68 °C, 180 s) and 68 °C, 7min.
The PCR products were visualized with UV-light on a 0.8% agarose E-
gel (Thermo Fisher Scientific) and then purified with the High Pure PCR
Product Purification Kit (Roche, Denmark). Thereafter, the sample was
sent for whole genome sequencing on the Illumina MiSeq platform at
Statens Serum Institut (Copenhagen, Denmark).
2.4.5. Conventional PCR and Sanger sequencing
Samples from pigs either testing positive for IAV for more than two
consecutive sampling times, and samples from pigs testing positive for
IAV at non-consecutive sampling times with minimum two negative
sampling time points in between, were chosen for Sanger sequencing of
the hemagglutinin (HA) and neuraminidase (NA) genes. The primers
listed in Table 1 were used for the PCR along with the SuperScript™ III
One-Step RT-PCR System with Platinum™ Taq DNA Polymerase kit
P. Ryt-Hansen, et al. Research in Veterinary Science 127 (2019) 47–56
48
(Thermofisher Scientific, Copenhagen, Denmark). The PCR was run on
the T3 thermocycler (Biometra, Fredensborg, Denmark) with the fol-
lowing program for the HA gene: 55 °C for 30min, 94 °C for 2min, 4×
(94 °C for 30 s, 55 °C for 30 s and 68 °C for 180 s), 41× (94 °C for 30 s
and 68 °C for 210 s) and 68 °C for 10min and the following program for
the NA gene: 54 °C for 30min, 94 °C for 2min, 4× (94 °C for 30 s, 58 °C
for 30 s and 68 °C for 180 s), 41× (94 °C for 30 s and 68 °C for 210 s)
and 68 °C for 10min. The PCR product was thereafter visualized on a
gel and purified, as described above for the NGS sequencing. The pur-
ified PCR products were sent for Sanger sequencing with the PCR pri-
mers at LGC Genomics (Berlin, Germany).
2.4.6. Generation of consensus sequences
The whole genome sequencing data was imported into the program
CLC genomics Workbench version 11.0.1. The reads were paired and
trimmed, and then mapped against a set of 22 reference segments,
covering all IAV segments known to circulate in Denmark. The mapping
result with the highest number of reads and the correct consensus
length was used to extract a consensus sequence for each of the eight
genome segments. The HA consensus sequence was translated into
amino acids. The Sanger sequencing data was imported into CLC main
workbench version 8, and were assembled against reference sequences
of the HA and NA genes. The reference sequences used were sequences
with the highest scoring sequence identity to the forward and reverse
reads using the function “BLAST against NCBI”. The sequences where
then manually proofread and the consensus sequence of each sample
was extracted and translated to amino acids.
2.4.7. Analysis of the consensus sequences
To confirm the subtype(s) of the IAV strain circulating in the herd, all
HA and NA genes were aligned with contemporary HA and NA sequences
obtained in the Danish annual swine IAV surveillance and a neighbor-
joining tree was constructed. Thereafter, all HA and NA nucleotide and
amino acid consensus sequences were aligned using the MUSCLE algo-
rithm (Edgar, 2004) and compared using the “pairwise comparison” tool
in CLC main workbench version 8. A similar, alignment and comparison
was also performed for both the HA and NA consensus sequences of the
herd strain against the respective vaccine consensus HA and NA se-
quence. The HA of A/swine/Haselünne_IDT_2617_2003 (H1N1) with
accession number: GQ161124 (nucleotides) and ACR39185 (amino
acids) was used for the HA alignment and the NA of A/swine/Bakum/
IDT1769/2003 (H3N2) with accession number GQ161100 (nucleotides)
and ACR39300 (amino acids) was used for the NA alignment. To in-
vestigate if amino acid differences between the herd strains and the
vaccine strain were in any of the known antigenic sites of the HA protein
(Caton et al., 1982; Manicassamy et al., 2010; Rudneva et al., 2012; Yang
et al., 2012), the location of the sites were annotated to each amino acid
sequence in the alignment. Finally, to reveal any sequence differences
between the HA sequence obtained from the same pig at different sam-
pling times (prolonged or recurrent shedders) the HA consensus se-
quences of the same pig were individually aligned and compared as
described above, and the same antigenic sites were annotated to the
amino acid sequences. The consensus sequences of each internal gene (M,
NS, NP, PA, PB1 and PB2) was investigated for the closest sequence
identity in GenBank using the function “BLAST against NCBI” to de-
termine if they were of avian or pandemic (A(H1N1)pdm09) origin. In
addition, to confirm the BLAST results, all the internal genes were se-
parately aligned with contemporary internal gene sequences obtained in
the Danish swine IAV surveillance program and a neighbor-joining tree
was constructed.
2.5. Statistical analyses
Sample size calculations were based on an average weight at
weaning of 6.0 kg with a standard deviation of 1.0 kg. With a sig-
nificance of 5%, a power of 80%, the required samples size of a two-
sided test, was 63 piglets per group to prove a difference in weight at
weaning of 0.5 kg statistically significant (Houe et al., 2004).
For comparison of clinical signs (lacrimation, nasal discharge or
conjunctivitis) between VAC and control pigs a Pearson's Chi-squared
Test was performed.
For an overall statistical comparison of means from normally dis-
tributed data (e.g. mean weight between VAC and control pigs), a
Student's t-Test was performed. In addition, the pigs were divided into
two groups based on the average Ct value of all positive nasal swabs
during the entire study period. Pigs with a Ct value higher than the
average Ct value were defined as “low infection level”, and pigs with a
lower or equal ct value than the average were defined as “high infection
level”. Since the two treatment groups were equally distributed ac-
cording to infection level the analysis of “low infection level”/”high
infection level” were done without including vaccination status. The
relationship between infection level (low/high) and the mean weight
were analyzed with a Student's t-Test and clinical signs with a Pearson's
Chi-squared Test. Furthermore, the impact of transfer of pigs between
sows on clinical signs, infection level and weight were analyzed with
Pearson's Chi-squared Test and a Student's t-Test, respectively. The
antibody status of the sows (positive/negative) at week 0 was tested for
correlation to the number of virus positive and negative piglets at the
different sampling times, using a Pearson's Chi-squared Test.
Each time point (0–6) was analyzed both separately and in total.
Statistical analyses were computed in R version 3.5.1 (R Core Team
2018).
3. Results
A total of 160 piglets from 11 sows were included in the study at
week 0, of which 80 received vaccination with Respiporc FLU3 and 80
were sham vaccinated with physiological saline, 9 mg/mL (control).
Between week 0 and week 2, 52 piglets died due to diarrhea. By the end
of the study, 102 piglets were still alive (Table 2).
3.1. Clinical signs
One day after vaccination, none of the pigs experienced pyrexia.
The mean rectal temperature was 38.8 °C (sd= 0.6) in the vaccinated
group and 38.8 (sd=0.6) in the control group.
Results of the weekly clinical examinations of the pigs in both
treatments groups independently of their IAV status are shown in
Table 1
Primers for conventional PCR of the HA and NA genes.
Sequence
HA-gene
Forward primer (pQE-HA-S-F) 5′- CGG ATA ACA ATT TCA CAC AGA GCA AAA GCA GGG GAW AAT W -3′
Reverse primer (pQE-HA-R) 5′- GTT CTG AGG TCA TTA CTG GAG TAG AAA CAA GGG TGT TTT -3
NA-gene
Forward primer (pQE-NA-F) 5′- CGG ATA ACA ATT TCA CAC AGA GCA AAA GCA GGA GT -3
Reverse primer (pQE-NA-R) 5′- GTT CTG AGG TCA TTA CTG GAG TAG AAA CAA GGA GTT TTT T -3′
W=A or T according to the IUPAC nucleotide code.
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Table 2. When considering the weekly clinical signs of the pigs in both
treatments groups, both positive and negative correlations were dis-
covered, and no significant difference was consistent over more than
one sampling time (Table 2).
The total number of pigs showing any of the clinical signs over the
whole study period (sum of all weeks) was compared to the treatment
group, stable unit, IAV presence and level, body condition score,
transfer between sows and antibody status of the sows. No significant
difference was observed in any of the clinical signs between the treat-
ment groups. However, a strong significant correlation (p < .001) was
found between the presence of nasal discharge and the presence of IAV
in the nasal swabs, independently of the treatment group. The presence
of at least one of the three clinical signs of respiratory disease; nasal
discharge, conjunctivitis or lacrimation also had a significant correla-
tion to the presence of IAV independently of the treatment group
(p≤.05). A slightly weaker and non-significant correlation (p= .078)
between conjunctivitis and the presence of IAV was also found, in-
dependently of the treatment group. No correlation between lacrima-
tion and the presence of IAV was found, and no correlation was found
between the infection level (high or low) and the clinical signs.
Interestingly, the transfer of pigs between sows had both a negative
impact of the body condition score, fecal soiling and increased the
number of pigs showing one of the three clinical signs correlated to
respiratory disease (Supplementary Table 1).
The summed numbers of each of the clinical signs over the whole
study period of the virus positive pigs exclusively are listed in Table 3.
No significant differences were found when comparing the degree of
each of the clinical signs between the virus positive vaccinated pigs and
the virus positive control pigs.
3.2. Body weight
The mean body weight of the vaccinated group were1.34 kg
(sd=0.4) at week 0, 5.19 kg (sd=1.4) at week 3 and 8.25 kg
(sd=1.9) at week 6, whereas the mean weight of the control group
were 1.32 kg (sd=0.4) at week 0, 5.10 kg (sd= 1.5) at week 3 and
7.83 kg (sd= 2.4) at week 6 (Fig. 1). No significant differences in
average body weights were observed between the vaccinated pigs and
Table 2
Overview of total number of pigs, % IAV positive pigs, mean Ct values, infection level and clinical signs between the two groups (VAC and control) over each of the 6
sampling times and accumulated as a total.
Age (week) 0 (vaccination) 1 2 3 4F 4 N 5 6 Total
Stable unit Farrow Farrow Farrow Farrow Farrow Nursery Nursery Nursery
Number of piglets
Total 160 123 108 104 53 49 101 102 800
VAC 80 61 56 55 28 26 53 54 413
Control 80 62 52 49 25 23 48 48 387
Influenza virus positive pigs, n (%) 246
VAC 3 (3.8) 10 (16.4) 30 (53.6) 11 (20.0) 17 (63.0) 7 (26.9) 23 (43.4) 20 (37.0) 121
Control 5 (6.3) 9 (14.5) 26 (50.0) 10 (20.4) 14 (56.0) 17 (73.9) 28 (58.3) 16 (33.3) 125
Ct among virus positive pigs, mean
VAC 33.90 30.26 28.15 28.56 28.15 26.30 30.37 30.57 29.2
Control 30.11 30.86 26.39 26.84 28.47 30.90 30.05 30.32 29.1
Influenza virus, pigs with high shedding (Ct < 29.19), n (%)
VAC 0 (0) 2 (3.2) 14 (25.0) 3 (5.4) 5 (23.8) 4 (15.4) 7 (13.2) 5 (9.3) 40 (9.7)
Control 2 (2.5) 1 (1.6) 15 (28.8) 7 (14.3) 6 (33.3) 3 (13.0) 8 (16.7) 5 (10.4) 47 (12.1)
Clinical signs, n (%)
Lacrimation 25 (3.1)
VAC 4 (5.0) 1 (1.6) 0 (0.0) 0 (0.0) 2 (7.1) 0 (0.0) 1 (1.9) 0 (0.0) 8 (1.9)
Control 10 (12.5) 2 (3.2) 1 (1.9) 2 (4.1) 1 (4.0) 0 (0.0) 1 (2.0) 0 (0.0) 17 (4.4)
Nasal discharge 380 (47.6)
VAC 8 (10.0) 33 (54.1) 21 (37.5) 39 (70.9) 23 (82.1) 3 (11.5) 28 (52.8) 49 (90.7) 204 (49.4)
Control 11 (13.8) 22 (35.5) 12 (23.1) 33 (67.3) 22 (88.0) 10 (43.5) 34 (69.4) 32 (69.6) 176 (45.6)
Conjunctivitis 289 (36.2)
VAC 14 (17.5) 22 (36.1) 30 (53.6) 34 (61.8) 17 (60.7) 12 (46.2) 9 (17.0) 17 (31.5) 155 (37.5)
Control 24 (30.0) 25 (40.3) 30 (57.7) 13 (26.5) 10 (40.0) 8 (34.8) 12 (24.5) 12 (26.1) 134 (34.7)
Pigs with either lacrimation, nasal discharge or conjunctivitis 540 (67.6)
VAC 24 (30.0) 48 (78.7) 39 (69.6) 46 (83.6) 23 (82.1) 14 (53.8) 31 (58.5) 50 (92.6) 275 (66.6)
Control 37 (46.3) 42 (67.7) 38 (73.1) 35 (71.4) 22 (88.0) 16 (69.6) 39 (79.6) 36 (78.3) 265 (68.6)
Poor body score 294 (36.8)
VAC 41 (51.2) 23 (37.7) 14 (25.0) 15 (27.3) 6 (22.2) 9 (34.6) 13 (24.5) 17 (31.5) 138 (20.3)
Control 43 (53.8) 26 (41.9) 12 (23.1) 13 (26.5) 8 (32.0) 11 (47.8) 23 (46.9) 20 (42.6) 156 (22.2)
Fecal soiling 170 (21.3)
VAC 24 (30.0) 17 (27.9) 10 (17.9) 5 (12.7) 1 (3.6) 2 (7.7) 17 (32.1) 6 (11.1) 84 (20.3)
Control 24 (30.0) 17 (27.4) 9 (17.3) 7 (10.2) 2 (8.0) 2 (8.7) 18 (36.7) 9 (19.6) 86 (22.3)
The results are listed as pig age group (in weeks) along with the stable unit in which the pigs were present when sampled. The pigs are further divided into treatment
group (VAC vs Control) when tested against the different parameters. Statistically significantly different results (p < .05) between the VAC/Control groups
(p < .05) are highlighted in bold.
Table 3
Prevalence of clinical signs in IAV positive pigs of the two treatments groups.
Lacrimation Nasal discharge Conjunctivitis Respiratory signs≥ 1 Poor body score Fecal soiling
Observations in total, n 799 799 799 799 799 799
Cases, n (% of total) 24 (3.1%) 376 (47.6%) 286 (36.2%) 537 (67.6%) 294 (37.0%) 170 (21.3%)
Virus positive, n 4 142 100 182 79 55
VAC, n 1 (25%) 72 (50.7%) 57 (57%) 89 (49.9%) 31 (39.2%) 22 (40%)
Control, n 3 (75%) 70 (49.3%) 43 (43%) 93 (51%) 48 (60.8%) 33 (60%)
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control pigs at any of the three sampling times. However, a significant
lower bodyweight was revealed in the IAV positive pigs at week 6
compared to IAV negative pigs, which weighed 1.7 kg more. Further-
more, the infection level, defined ashigher or lower than the average Ct
value (29.2, described in the section “Level of virus in nasal swabs”)
also had a significant impact on the body weight at week 6, as the pigs
with a “high infection level” weighed 1.47 kg less than the pigs with
“low infection level” (Supplementary Table 2).
3.3. Serology
The blood samples obtained from the sows at week 0 revealed that
the majority of the sows (9/11) were positive for antibodies against
IAV.
There was no significant difference in the percentage of seropositive
piglets at week 3 between the two treatment groups in that 80% of the
controls and 73% of the vaccinated pigs were antibody positive and the
average OD-ratio did not differ significantly between the two treatment
groups (control: 0.48 and vaccinated: 0.49) (data not shown).
3.4. Prevalence of IAV
The percentage of piglets testing positive for IAV in nasal swabs
over the study period is shown in Fig. 2. Already at the time of cas-
tration (day 3–4), eight piglets tested positive for IAV in nasal swabs.
The prevalence of virus positive piglets then increased markedly and at
week 2 approx. 50% of all pigs of both groups tested positive for IAV in
the nasal swabs. At week 3, a decrease in the prevalence was observed
and then the prevalence increased again after weaning (week 4), where
most of the pigs were mixed in the nursery stables. The only significant
difference in the number of IAV positive pigs between the two groups
was observed at the first sampling in the nursery unit (W4N) where a
significant higher number of IAV positive piglets were present in the
control group compared to the vaccinated group. The results revealed
that all but one pig, which survived throughout the study period tested
positive for IAV at some point during the study, resulting in no overall
difference in the total number of infected pigs between the two treat-
ment groups (Supplementary Table 3).
The percentage of virus positive pigs originating from either an
antibody positive or negative sow is shown in Fig. 3. Although the
number of seronegative sows was very low (2/11 sows), there was a
significant higher number of pigs from antibody negative sows that
became infected during the first three sampling times at weeks 0, 1 and
2 compared to piglets from the seropositive sows. In contrast, the
prevalence of positive piglets was the same at weeks 3–5 irrespectively
of the antibody status of the sow, but, interestingly, significantly more
pigs from the antibody positive sows were infected at week 6. However,
no significant difference was observed in the total percentage of IAV
positive piglets between the two treatment groups.
3.5. Duration of shedding time and virus subtype
In total, seven pigs from the vaccinated group and eleven pigs from
the control group tested positive for IAV in the nasal swabs over three
consecutive sampling times and one piglet from the control group
Fig. 1. Boxplot showing the weight of the pigs of the two groups (control vs vaccine) at the three weighing times (week 0, 3 and 6).
Fig. 2. Prevalence of IAV in nasal swabs of the control and vaccinated (VAC)
groups over the different sampling times (W0–W6).
W4F: samples taken in week 4 in the farrowing unit. W4N: samples taken in
week 4 in the nursery unit.
⁎Indicates a significant difference (p < .05) between the two groups.
P. Ryt-Hansen, et al. Research in Veterinary Science 127 (2019) 47–56
51
tested positive for IAV over four consecutive sampling points. We de-
fined these pigs as “prolonged shedders”. Furthermore, 14 pigs tested
positive for IAV at nonconsecutive sampling points separated by two or
three sampling times. This number included eleven nonconsecutive
shedders from the vaccinated group and three from the control group
(Supplementary Table 3). We defined these pigs as “recurrent shed-
ders”.
All samples of the study with a Ct value<31 (n=45) were sub-
typed by a multiplex RT-real time PCR and revealed the herd subtype to
be of H1avN2sw origin (data not shown).
3.6. Level of virus in nasal swabs
Fig. 4 list the viral load (estimated as average Ct values) in the nasal
swabs of the positive pigs from both treatment groups during the study
period. The only significant difference in viral load was in the pigs in
the nursery unit at week 4. Unexpectedly, the vaccinated pigs had a
higher level of viral shedding compared to unvaccinated controls.
The range in average Ct values of the two treatment groups was
between 26.3 and 33.9 (Table 2). The average Ct value based on all the
results of all piglets at all sampling times was 29.2, and this value was,
as previously mentioned, used as a cut off for defining the pigs as
having a “high infection level” or a “low infection level”. When using
this definition of infection level it was evident that there was no sig-
nificant difference between the numbers of pigs with high and low in-
fection level according to vaccination status (Table 2).
3.7. Genetic characterization of the herd IAV strain
Full genome sequences of all eight segments of the herd strain were
obtained. The results revealed that the sample was of the H1avN2sw
subtype, which agreed with the results of the multiplex RT-real time
PCR. Moreover, the results of the BLAST revealed that the M, NP, PA,
PB1 and PB2 genes were of the pandemic A(H1N1)pdm09 origin,
whereas the NS gene was of avian origin. The full genome sequences
from this study are available in the NCBI Genbank with the following
accession numbers: MN249749-MN249756. The Sanger sequencing
results derived from a total of 21 samples confirmed the HA and NA
subtype and thereby documented that only one strain was circulating in
the herd throughout the study period. The HA sequence identity of the
viruses from the herd ranged between 98.7 and 100% at nucleotide
level and 97.9–100% at amino acid level, and the NA sequence identity
ranged between 99.2 and 100% at nucleotide level and 99–100% on the
amino acid level.
3.8. Sequence identity of the herd IAV strain to the vaccine strain
Pairwise comparison of the HA sequences of the herd strain and the
HA sequence of the vaccine strain (Haselünne_IDT_2617_2003 (H1N1))
revealed a 89.5–90.2% identity on nucleotide level and 90.2–91.4% on
amino acid level corresponding to 48–55 amino acid differences. Eight
of these amino acid differences were found in antigenic sites (Sa, Sb, Cb,
Ca1 and Ca2) (Caton et al., 1982; Manicassamy et al., 2010; Rudneva
et al., 2012; Yang et al., 2012) and included the following differences
compared to the vaccine strain; V90A, D91N, N142H, N159K, K170G,
G172K, N173G and G239E. The position of amino acid changes were
numbered according to the first Methionine (H1 numbering). The
pairwise comparison of the NA sequences to NA sequence of the vaccine
strain (Bakum/IDT1769/2003 (H3N2)) revealed 88% sequence identity
on the nucleotide level and 89% on the amino acid level.
3.9. Sequence identity among IAV strains isolated from the prolonged- and
the recurrent shedders
As mentioned earlier, 18 pigs tested positive for IAV over a
minimum of three sampling times, which we defined as “prolonged
shedders”, and 14 pigs in total tested positive for IAV twice separated
with two to three sampling times, which we defined as “recurrent
shedders”. Consensus sequences of the HA gene from at least two dif-
ferent sampling times were successfully obtained from four recurrent
shedders (N78, V81, V85 and V89) and from five prolonged shedders
(N36, N38, V45, V57 and N136). For the prolonged shedders no or few
(≤5) nucleotide changes were observed between sequences obtained
from the same pig at different sampling times, and only in two of the
pigs, the nucleotide difference resulted in amino acid changes (I387S,
V389I for pig N38 and K40N for pig N136). Pig V45 was categorized as
a “prolonged shedders” but - despite it only tested negative in week 5 –
the piglet also behaved as a “recurrent shedder” as it first tested positive
for IAV at week 2, 3 and 4, and then tested negative at week 5 and
positive again at week 6 with a relatively low Ct value. Sequencing of
samples from pig V45 revealed that at weeks 2 and 3 the HA gene was
100% identical, whereas at week 6, 12 nucleotide mutations had oc-
curred, resulting in seven amino acid changes. The HA gene was se-
quenced from five pigs including V45 with recurrent infections. All
recurrent shedders showed between one and 17 nucleotide substitu-
tions between samplings, and in all pigs at least one of the nucleotide
changes resulted in amino acid changes. Of the five pigs with recurrent
infection, identical amino acid changes were shared at position 159,
235, 331, 387 and 389, meaning that two-three pigs showed identical
mutations. Interestingly, three of these five mutations were located in
HA1 which encodes the globular head of the HA protein (Steinhauer
and Skehel, 2002), which is the main target for neutralizing antibodies.
In addition, one of these positions (159) was located in the antigenic
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Fig. 3. Prevalence of IAV positive pigs from seropositive or seronegative sows
over the different sampling times (W0–W6).
W4F: samples taken in week 4 in the farrowing unit. W4N: samples taken in
week 4 in the nursery unit.
⁎Indicates a significant difference (p < .05) between the two groups.
Fig. 4. Average Ct values of the IAV positive pigs of the control and vaccinated
(VAC) groups over the different sampling times (W0–W6).
W4F: samples taken in week 4 in the farrowing unit. W4N: samples taken in
week 4 in the nursery unit.
⁎Indicates a significant difference (p < .05) between the two groups.
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site Ca2, and the same mutation K159R occurred in two different pigs
(N78 and V81). The HA and NA sequences of this study are available in
the NCBI Genbank with the following accession numbers: MN263260-
MN263291.
4. Discussion
No adverse effects of experimental vaccination with a reduced dose
of Respiporc FLU3were encountered during the study indicating that
vaccination of very young piglets is safe despite of it being “off label”
use of the vaccine. The impact of vaccination of piglets was, however,
vague. Significant differences in clinical signs between the vaccinated
and the control group were observed, when analyzing each sampling
time separately, however, the differences were not always to the benefit
of the vaccinated pigs and they were not consistent over more sampling
times. In addition, no evidence of clinical protection was identified in
the vaccinated group. Furthermore, the body weights at weeks 0, 3 and
6 were not significantly different between the two treatment groups,
which suggested that vaccination of very young piglets did not results
in a higher average daily weight gain. This was further emphasized by
the fact that no differences in the prevalence of pigs with a poor body
condition score between the vaccinated and the control pigs were ob-
served.
The transfer of the piglets between different sows or pens had a
negative impact on the body weight, the body score, fecal soiling and
resulted in more pigs with one or more clinical signs of respiratory
disease independent of IAV vaccination. This underlines that transfer of
pigs between pens presents a major risk factor for comprised health and
might not have the desired effect in weight gain either. Furthermore,
the extensive mixing of piglets between litters and use of nursing sows
in this herd present a high risk for the spread of IAV infections, and help
explain the high infection level observed in the farrowing unit.
Moreover, all gilts of the herd were introduced from an external source
without any quarantine, thereby contributing to the maintenance of
IAV circulation but also inducing a risk of novel IAV introductions.
The overall prevalence of IAV in both the vaccinated and the control
group was very high and there were no overall differences between the
two treatment groups. The only significant difference in the number of
pigs testing positive for IAV was observed at week 4 among the weaned
pigs in the nursery unit. At this time point, significant higher numbers
of IAV positive pigs were identified in the control group compared to
the vaccinated group. This suggested that vaccination of the piglets
during week 1 decreased the number of susceptible pigs after weaning.
However, the number of pigs present in the nursery at week 4 was
limited, and the difference in susceptibility was not sustained in the
following weeks and, as mentioned above, the overall prevalence did
not vary between the two groups. In addition, the IAV positive vacci-
nated pigs present in the nursery at week 4 had a significantly lower
average Ct value, indicating that the vaccinated pigs shed more virus.
Therefore, the impact of difference observed at week 4 is inconclusive.
It could be argued that the study design itself made it difficult to ob-
serve any benefit of vaccination, as vaccinated and control pigs were
present in the same pen and in the same stable. However, the ad-
vantages of the chosen study design were the presence of natural
transmission dynamics of IAV in the pens and a no bias in relations to
the sows.
The presence of IAV was correlated to clinical signs of respiratory
disease. Especially nasal discharge was strongly correlated with detec-
tion of IAV in the nasal swab, which confirms the result of a previous
study investigating the impacts of IAV in the farrowing and nursery
units (Ryt-Hansen et al., 2019). In addition, the presence of IAV at week
6 was also correlated with a lower weight. Together, these results
emphasize that IAV indeed has a clinical and economic impact in swine
herds as described in other studies (Brown et al., 1993; Er et al., 2014;
Ferrari et al., 2009; Loeffen et al., 2009; Ryt-Hansen et al., 2019; Van
Reeth et al., 1996).
The results from the antibody ELISA test indicated that vaccination
of piglets during week 1 did not increase the prevalence of seropositive
piglets in week 3 compared to unvaccinated pen-mates in that approx.
20% of the piglets from both groups were seronegative in week 3. This
could be due to the vaccination procedure used in this herd. According
to the Summary of Product Characteristics (SPC) for Respiporc FLU3
the dose per pig is 2mL administered twice. The choice to use only
0.5 mL once was made because this is the standard dosing regimen used
by most Danish veterinary practitioners. This is not based on any sci-
entific evidence, but merely a choice made empirically to reduce the
price and to mitigate risk of side effects. Furthermore, no booster were
given because the aim of the vaccination was to control the infection
the farrowing unit. Another explanation for the lack of seroconversion
could be that the piglet's immune system was not able to respond to this
vaccination at such an early age. Nevertheless, previous studies on
piglet vaccination against PCV2 at day 5 and Mycoplasma hyopneumo-
niae at 1 week of age (O'Neill et al., 2011; Reynolds et al., 2009; Wilson
et al., 2013) suggested that the immune system is indeed able to re-
spond efficiently to vaccination. Another more likely explanation is that
the presence of maternal derived antibodies interfered with the vacci-
nation (Loeffen et al., 2003; Renshaw, 1975), and hindered an active
immune response in the piglet. However, lack of seroconversion was
also seen in piglets from seronegative sows and the number of infected
and vaccinated pigs from seropositive- and seronegative sows did not
differ. Since no samples were taken from the colostrum or from new-
born pigs, the possibility that the piglets did receive MDA despite the
seronegative status of the sow cannot be confirmed.
The most likely explanation for the lack of effect of vaccination in
the present herd was the fact that the piglets were infected very early in
life – before a response to vaccination could be anticipated. Piglets at
only four days of age became infected and the peak of infection was
observed already at week 2. These results confirm the results of a
previous study (Ryt-Hansen et al., 2019) and emphasize that in some
herds it is extremely challenging to stimulate an antibody response
before the pigs are naturally infected. Moreover, the low dosing re-
gimen used, the inhibitory effect of MDA and strain diversity may also
have an impact on the efficacy of the vaccine. Indeed, the level of
homology between the vaccine strain and the circulating herd strain
should be taken into consideration when evaluating the effect of vac-
cination. The HA of the circulating strain of the herd and the HA of the
vaccine strain were of the same avian lineage, but shared only
90.2–91.4% amino acid identity. A clear correlation between amino
acid homology and level of cross protection has not been finally es-
tablished for swIAV, however, some of the amino acid differences be-
tween the vaccine strain and the field strain were located in specific
antigenic sites, indicating that these differences might have an impact
of antibody binding to the HA gene. However, further studies are
needed to evaluate the impact of this finding. Moreover, the NA genes
of the circulating strain and the vaccine strains were also found to vary.
The internal genes of the circulating strain were, with the exception of
the NS gene, of pandemic A(H1N1)pdm09 origin. However, the vaccine
(Respiporc FLU3) does not include any component of A(H1N1)pdm09
origin. A previous study has shown that some of the protective anti-
bodies induced by whole virus inactivated vaccine are also directed
against the internal genes such as the M or NP genes (Vincent et al.,
2017). Moreover, the internal genes also contain important epitopes for
the cellular immunity including T-cell responses (Gotch et al., 1987;
Yewdell et al., 1985). Therefore, it could be speculated that the mis-
match between the internal genes of the vaccine- and field strain im-
paired the efficacy of the vaccine; however, more studies are needed to
document this rather controversial hypothesis. A modified live viral
vaccine (MLV) for intra nasal use has recently been released for use in
the US and has been shown to be effective when used in piglets as early
as 1 day of age in the presence of MDA (Genzow et al., 2018; Vincent
et al., 2012, 2007). The difference between the two vaccines is that
inactivated vaccines mainly stimulates production of IgG, whereas the
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MLV vaccine also induces a local IgA response (Busquets et al., 2010;
Gould et al., 2017; Loeffen et al., 2003; Renegar et al., 2004; Seibert
et al., 2013).
Previous studies have suggested the possibility of pigs becoming re-
infected with the same strain (Chamba Pardo et al., 2019; Diaz et al.,
2017a; Ryt-Hansen et al., 2019; Simon-Grifé et al., 2012) and further-
more, piglets infected with IAV in the presence of MDA have been
shown to have prolonged IAV shedding time (Loeffen et al., 2003; Rose
et al., 2013). The present study design included very frequent sampling,
which allowed us to study this in more details. Indeed, prolonged
(consecutive) shedding of IAV for 2–3 weeks were documented along
with recurrent (non-consecutive) shedding indicating reinfection with
the same subtype. To sustain that the pigs indeed were infected with the
same strain, viral sequences were obtained from pigs considered to be
prolonged shedders and from pigs considered to be re-infected. The
sequence data clearly showed that only one virus strain of the
H1avN2sw subtype was circulating in the herd, which is the most
prevalent subtype found in Denmark (Watson et al., 2015). Further-
more, the sequences obtained from the prolonged shedders revealed
very close sequence homology, which indicated that these pigs were
shedding the same virus for at least 14 days. Few to no nucleotide
changes were observed in these animals. Similarly, the sequences ob-
tained from the recurrent shedders, indicated that pigs were indeed
capable of being re-infected with the same strain. However, in contrast
to the prolonged shedders, the HA sequence data revealed significant
differences between the strain collected at the “first” infection and the
“second” infection, and some of these changes were consistent between
different re-infected pigs. This indicated a strong selective pressure
because the amino acid changes clustered in known antigenic sites of
the HA gene. This finding is very important in large swine herds
chronically infected with IAV, because it will drive the evolution of
viral variants towards variants that can escape the immunity against the
field strain. Indeed, we have preliminary data that indicates that IAV in
chronically infected herds behave similar to human seasonal viruses
and undergo a stair-wise evolution and accumulate mutation in anti-
genic important sites (Ryt-Hansen, in preparation). These findings
emphasizes that viral drift of IAV is a reality also in swine and should be
considered in cases of vaccine-failure – especially in larger and un-
sectioned herds. Apart from genetic drift, the presence of MDA at the
time of infection may also predispose for re-infection. As MDAs have
been shown to weaken an active immune response to initial IAV in-
fection, there is a risk that when the MDAs wane, the pig can become
susceptible for re-infection with the same strain. Several studies have
indeed shown that the presence of MDA at the time of IAV infection
weakens a subsequent active immune response (Deblanc et al., 2018;
Loeffen et al., 2003; Markowska-Daniel et al., 2011; Niewiesk, 2014;
Rose et al., 2013). However, actual reinfection has only been shown in
one study (Loeffen et al., 2003). The accumulating evidence of pro-
longed shedding and re-infection with the same subtype and even strain
should be taken into consideration when investigating IAV dynamics
and transmission in the field.
5. Conclusion
The results of this study in a single herd revealed that there was no
beneficial effect of piglet vaccination with a reduced and single-shot
dosing regimen of Respiporc FLU3 at the time of castration. The main
reason for the lack of protection was probably the early infection time
combined with the reduced dosing regimen used, which made it chal-
lenging to obtain a vaccine response before infection. The results of the
study confirmed that IAV infection results in clinical signs of respiratory
disease and that a negative effect on body weight should be expected in
herds with circulating IAV in the farrowing and nursery unit. In addi-
tion, more evidence of prolonged shedding of IAV and re-infections
with the same strain were provided and the results emphasized that the
dynamics of IAV in the herds are even more complex than previously
perceived. IAV is indeed a fast evolving pathogen and viral drift might
be the reason for re-infections and thereby present an additional chal-
lenge for the control of the disease in the field.
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